Nektar released topline Phase 2b REZOLVE-AA results (92 patients with severe-to-very-severe AA) in December 2025, describing a 'meaningful level of clinical effect'; full data planned for presentation at a 2026 medical conference, with 16-week extension data expected early Q2 2026.
- Lab
- Phase 1
- Phase 2
- Phase 3
- Approved
Phase 2
How it works
Engineered IL-2 variant ('IL-2 mutein') designed to selectively expand regulatory T cells to restore immune tolerance and stop the autoimmune attack on hair follicles.
Results so far
Specific response-rate numbers were not captured in the search snippets reviewed (only qualitative 'meaningful clinical effect' language) — flag for verification against Nektar's primary IR release before quoting figures.
What's next
Full data presentation expected at a medical conference in 2026; next clinical step (Phase 3) not yet announced in sources reviewed.
In India
No India-specific development identified.
Sources
- Company announcement ↗ (accessed 2026-10-17)
- News report ↗ (accessed 2026-10-17)
- News report ↗ (accessed 2026-10-17)
What to do today: treatments in development aren't a reason to wait. Ask a dermatologist about the options that work now, such as minoxidil, or see alopecia areata treatments.
Discussion
Share your experience or ask a question. New members' posts are reviewed before they appear.